prorenoate potassium: RN given refers to (6 alpha,7 alpha,17 alpha)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 23667640 |
| CHEMBL ID | 2107002 |
| SCHEMBL ID | 123301 |
| MeSH ID | M0056527 |
| Synonym |
|---|
| 3'h-cyclopropa(6,7)pregna-4,6-diene-21-carboxylic acid, 6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6-alpha,7-alpha,17-alpha)- |
| potassium 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylate |
| sc 23992 |
| prorenoato potasico [inn-spanish] |
| 3'h-cyclopropa(6,7)pregna-4,6-diene-21-carboxylic acid, 6,7-dihydro-17-hydroxy-3-oxo-, (6alpha,7alpha,17alpha)-, monopotassium salt |
| prorenoate potassique [inn-french] |
| potassium prorenoate |
| prorenoate potassium (usan/inn) |
| D05640 |
| 49847-97-4 |
| sc-23992 |
| prorenoate potassium |
| CHEMBL2107002 |
| t2d4xus623 , |
| prorenoato potasico |
| unii-t2d4xus623 |
| prorenoate potassique |
| prorenoate potassium [usan:inn:ban] |
| SCHEMBL123301 |
| 3'h-cyclopropa(6,7)pregna-4,6-diene-21-carboxylic acid, 6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6-.alpha.,7-.alpha.,17-.alpha.)- |
| 3'h-cyclopropa(6,7)pregna-4,6-diene-21-carboxylic acid, 6,7-dihydro-17-hydroxy-3-oxo-, (6.alpha.,7.alpha.,17.alpha.)-, monopotassium salt |
| prorenoate potassium [usan] |
| prorenoate potassium [inn] |
| potassium;3-[(1r,2r,4r,10r,11s,14s,15r,18s)-15-hydroxy-10,14-dimethyl-7-oxo-15-pentacyclo[9.7.0.02,4.05,10.014,18]octadec-5-enyl]propanoate |
| DTXSID90964445 |
| Q27289573 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "1 The pharmacodynamic profile of single oral doses of prorenoate potassium (40 mg) and spironolactone (100 mg), as judged by reversal of the effects of fludrocostisone on the urinary electrolyte composition, was compared to that of placebo in a double-blind crossover study in six healthy subjects." | ( The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects. Ramsay, LE; Shelton, JR; Tidd, MJ, 1976) | 0.5 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose-related increases in thyroid-stimulating hormone (TSH) levels were observed in treated animals of both sexes during the dosing period and the changes were statistically significant and correlated with an increased thyroid weight in females at 13 weeks." | ( The pathologic response of the liver and thyroid of the rat to potassium prorenoate (SC-23992). Lumb, GD; Rust, JH, 1985) | 0.27 |
| " Log fludrocortisone dose-response relationships in the presence or absence of antagonists did not differ from linearity and parallelism, supporting the theoretical basis of the method." | ( Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate. Harrison, IR; McInnes, GT; Shelton, JR, 1981) | 0.26 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (27.27%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (63.64%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||